Answer
The court ordered Martin Shkreli, the former CEO of Turing Pharmaceuticals, to repay $64.6 million to victims in his antitrust civil case. This amount represents the profits he gained from illegally monopolizing the market for Daraprim, a life-saving drug used to treat toxoplasmosis. Shkreli's actions led to a significant increase in the price of Daraprim, causing hardship for patients who relied on the medication.